Treatment discontinuation with peg-interferon: what to consider

References

• Welch NM, Jensen DM. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int 2015;35(Suppl 1):11-17
   PubMed Web of Science ®Google Scholar
• Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatol 2007;45(3):579-87
   PubMed Web of Science ®Google Scholar
• Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308(24):2584-93
   PubMed Web of Science ®Google Scholar
• Boccaccio V, Bruno S. Optimal management of patients with chronic hepatitis C and comorbidities. Liver Int 2015;35(Suppl 1):35-43
   PubMed Web of Science ®Google Scholar
• Boccaccio V, Bruno S. Management of HCV patients with cirrhosis with direct acting antivirals. Liver Int 2014;34(Suppl 1):38-45
   PubMed Web of Science ®Google Scholar
• Andriulli A, Di Marco V, Margaglione M, et al. Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. J Hepatol 2014;60(1):16-21
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40(6):993-9
   PubMed Web of Science ®Google Scholar
• European association for study of liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
   PubMed Web of Science ®Google Scholar
• Bourlière M, Benali S, Ansaldi C, et al. Optimal therapy of genotype-2 chronic hepatitis C: what’s new? Liver Int 2015;35(Suppl 1):21-6
   PubMed Web of Science ®Google Scholar
• Abdel-Razek W, Waked I. Optimal therapy in genotype 4 chronic hepatitis C: finally cured? Liver Int 2015;35(Suppl 1):27-34
   PubMed Web of Science ®Google Scholar
• Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40 KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010;51(2):388-97
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376(9742):705-16
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone JJr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195-206
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207-17
   PubMed Web of Science ®Google Scholar
• Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 2013;59(3):434-41
   PubMed Web of Science ®Google Scholar
• Bruno S, Bollani S, Zignego AL, et al. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. J Viral Hepat 2015;22(5):469-80
   PubMed Web of Science ®Google Scholar
• Bruno S, Vierling JM, Esteban R, et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013;58:479-87
   PubMed Web of Science ®Google Scholar
• Hézode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterol 2014;147(1):132-42.e4
   PubMed Web of Science ®Google Scholar
• Colombo M, Strasser S, Moreno C, et al. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. J Hepatol 2014;61(5):976-83
   PubMed Web of Science ®Google Scholar
• Bailly F, Virlogeux V, Dufour C, et al. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study. Clin Res Hepatol Gastroenterol 2015. [Epub ahead of print]
   Google Scholar
• Cento V, Di Paolo D, Di Carlo D, et al. Hepatitis C virus RNA levels at week-2 telaprevir/boceprevir administration are predictive of virological outcome. Dig Liver Dis 2015;47(2):157-63
   PubMedGoogle Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878-87
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015;61(3):769-75
   PubMed Web of Science ®Google Scholar
• Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naïve chronic hepatitis C genotype 1 or 4 infection: a randomized study. Gut 2014
   PubMed Web of Science ®Google Scholar
• Dore GJ, Lawitz E, Hézode C, et al. Daclatasvir plus peginterferon and ribavirin is non inferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Gastroenterol 2015;148(2):355-366.e1
   PubMed Web of Science ®Google Scholar
• Jacobson I, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384(9941):403-13
   PubMed Web of Science ®Google Scholar
• Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384(9941):414-26
   PubMed Web of Science ®Google Scholar
• Cure S, Guerra I, Cammà C, et al. Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy. J Med Econ 2015;1-13
   Web of Science ®Google Scholar
• Ronzoni L, Aghemo A, Rumi MG, et al. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients. J Viral Hepat 2014;21(6):416-23
   PubMed Web of Science ®Google Scholar
• Dultz G, Seelhof M, Herrmann E, et al. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis. PLoS One 2013;8(8):e71262
   Google Scholar
• Bruno S, Sewpaul P, Russo ML, et al. 12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post-hoc analysis of eltrombopag studies. Dig Liver Dis 2015
   Google Scholar
• Dvory-Sobol H, Wyles D, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor Ledipasvir. J Hepatol 2015;62(Suppl 2):S221
   Google Scholar
• Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with Paritaprevir/r-, Ombitasvir- and Dasabuvir-based regimens. J Hepatol 2015;62(Suppl 2):S220
   Web of Science ®Google Scholar
• Bruno S, Thompson AJ, Critelli R, et al. Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a longe-term cohort study. Antiviral Res 2015;113:27-32
   PubMed Web of Science ®Google Scholar
• Boccato S, Pistis R, Noventa F, et al. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat 2006;13(5):297-302
   PubMed Web of Science ®Google Scholar
• Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009;50(4):1038-44
   PubMed Web of Science ®Google Scholar